These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33570402)

  • 1. Curaxin-Induced DNA Topology Alterations Trigger the Distinct Binding Response of CTCF and FACT at the Single-Molecule Level.
    Lu K; Liu C; Liu Y; Luo A; Chen J; Lei Z; Kong J; Xiao X; Zhang S; Wang YZ; Ma L; Dou SX; Wang PY; Li M; Li G; Li W; Chen P
    Biochemistry; 2021 Feb; 60(7):494-499. PubMed ID: 33570402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-cancer drugs curaxins target spatial genome organization.
    Kantidze OL; Luzhin AV; Nizovtseva EV; Safina A; Valieva ME; Golov AK; Velichko AK; Lyubitelev AV; Feofanov AV; Gurova KV; Studitsky VM; Razin SV
    Nat Commun; 2019 Mar; 10(1):1441. PubMed ID: 30926878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers.
    Dallavalle S; Mattio LM; Artali R; Musso L; Aviñó A; Fàbrega C; Eritja R; Gargallo R; Mazzini S
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
    Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
    Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel anticancer drug curaxin CBL0137 impairs DNA methylation by eukaryotic DNA methyltransferase Dnmt3a.
    Sergeev A; Vorobyov A; Yakubovskaya M; Kirsanova O; Gromova E
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127296. PubMed ID: 32631516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.
    Gasparian AV; Burkhart CA; Purmal AA; Brodsky L; Pal M; Saranadasa M; Bosykh DA; Commane M; Guryanova OA; Pal S; Safina A; Sviridov S; Koman IE; Veith J; Komar AA; Gudkov AV; Gurova KV
    Sci Transl Med; 2011 Aug; 3(95):95ra74. PubMed ID: 21832239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins.
    Chang HW; Valieva ME; Safina A; Chereji RV; Wang J; Kulaeva OI; Morozov AV; Kirpichnikov MP; Feofanov AV; Gurova KV; Studitsky VM
    Sci Adv; 2018 Nov; 4(11):eaav2131. PubMed ID: 30417101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
    Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
    Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTCF-Induced Circular DNA Complexes Observed by Atomic Force Microscopy.
    Mawhinney MT; Liu R; Lu F; Maksimoska J; Damico K; Marmorstein R; Lieberman PM; Urbanc B
    J Mol Biol; 2018 Mar; 430(6):759-776. PubMed ID: 29409905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy.
    Chen M; Brackett CM; Burdelya LG; Punnanitinont A; Patnaik SK; Matsuzaki J; Odunsi AO; Gudkov AV; Singh AK; Repasky EA; Gurova KV
    Cancer Immunol Immunother; 2021 Jul; 70(7):2073-2086. PubMed ID: 33439292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
    Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27650817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo.
    Fetisov TI; Borunova AA; Antipova AS; Antoshina EE; Trukhanova LS; Gorkova TG; Zuevskaya SN; Maslov A; Gurova K; Gudkov A; Lesovaya EA; Belitsky GA; Yakubovskaya MG; Kirsanov KI
    Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Colorectal Carcinogenesis by DNA-Binding Small-Molecule Curaxin CBL0137 Involves Suppression of Wnt Signaling.
    Kirsanov K; Fetisov T; Lesovaya EA; Maksimova V; Trukhanova L; Antoshina E; Gor'kova T; Morozova O; Safina A; Fleyshman D; Salimov R; Shipaeva E; Ivanov R; Leonov A; Purmal AA; Belitsky GA; Gudkov AV; Gurova KV; Yakubovskaya MG
    Cancer Prev Res (Phila); 2020 Jan; 13(1):53-64. PubMed ID: 31653646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs.
    Nesher E; Safina A; Aljahdali I; Portwood S; Wang ES; Koman I; Wang J; Gurova KV
    Cancer Res; 2018 Mar; 78(6):1431-1443. PubMed ID: 29339544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing
    De S; Lindner DJ; Coleman CJ; Wildey G; Dowlati A; Stark GR
    Cancer Res; 2018 May; 78(9):2396-2406. PubMed ID: 29440145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTCF driven TERRA transcription facilitates completion of telomere DNA replication.
    Beishline K; Vladimirova O; Tutton S; Wang Z; Deng Z; Lieberman PM
    Nat Commun; 2017 Dec; 8(1):2114. PubMed ID: 29235471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curaxin CBL0137 has the potential to reverse HIV-1 latency.
    Jean MJ; Zhou D; Fiches G; Kong W; Huang H; Purmal A; Gurova K; Santoso NG; Zhu J
    J Med Virol; 2019 Aug; 91(8):1571-1576. PubMed ID: 30989696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression.
    Shen J; Chen M; Lee D; Law CT; Wei L; Tsang FH; Chin DW; Cheng CL; Lee JM; Ng IO; Wong CC; Wong CM
    Gut; 2020 Feb; 69(2):329-342. PubMed ID: 31439637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of curaxin-dependent nucleosome unfolding by FACT.
    Volokh OI; Sivkina AL; Moiseenko AV; Popinako AV; Karlova MG; Valieva ME; Kotova EY; Kirpichnikov MP; Formosa T; Studitsky VM; Sokolova OS
    Front Mol Biosci; 2022; 9():1048117. PubMed ID: 36483541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.